Company newsMRNA
Explain this story: Biotech Stock Decoy Therapeutics (NASDAQ: DCOY) Leads Nasdaq Top Gainers on News of FDA Animal Rule Pathway
Decoy Therapeutics (NASDAQ: DCOY) shares became a top Nasdaq gainer after the company announced it is advancing a pan-filovirus D-MAV program through the FDA's Animal Rule pathway. This strategy aims for expedited regulatory approval and allows Decoy to pursue non-dilutive government grants and biodefense partnerships. The program targets Ebola, Marburg, Sudan, and Bundibugyo viruses, with potential eligibility for a Priority Review Voucher worth $100 million to $180 million.
OtherInvestorideas.comSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Decoy Therapeutics (NASDAQ: DCOY) shares became a top Nasdaq gainer after the company announced it is advancing a pan-filovirus D-MAV program through the FDA's Animal Rule pathway. This strategy aims for expedited regulatory approval and allows Decoy to pursue non-dilutive government grants and biodefense partnerships. The program targets Ebola, Marburg, Sudan, and Bundibugyo viruses, with potential eligibility for a Priority Review Voucher worth $100 million to $180 million.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 23, 2026, 06:24 ET · on this site +3d 19h